Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials

RTTNews | 186 days ago
Stocktwits
Eli Lilly Collaborates With OpenAI To Use Generative AI To Invent Novel Antimicrobials

(RTTNews) - Eli Lilly and Co. (LLY) announced Tuesday a collaboration with OpenAI that will allow Lilly to leverage OpenAI's generative AI to invent novel antimicrobials to treat drug-resistant pathogens.

Antimicrobial resistance (AMR) is one of the top public health and development threats across the global health landscape. The misuse and overuse of antimicrobials in humans, animals and plants are the main drivers in the development of drug-resistant pathogens, magnifying this threat to global health.

This collaboration with OpenAI supports Lilly's earlier commitment to fighting drug-resistant pathogens through its Social Impact Venture Capital Portfolio.

In 2020, the portfolio committed $100 million to the AMR Action Fund, aiming to provide patients with two to four new antibiotics by 2030 and contribute the next line of defense against multi-drug-resistant pathogens.

In April 2023, the AMR Action Fund announced its latest investments in biotech companies targeting a range of infections.

Tags: LLY
Stocktwits
read more
Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook

Eli Lilly Q2 Results Top Estimates; Boosts FY24 Outlook

Drugmaker Eli Lilly reported Thursday a net profit for the second quarter that surged 68 percent from last year, reflecting strong Mounjaro, Zepbound and Verzenio sales as well as higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also raised its guidance for the full-year 2024.
RTTNews | 142 days ago
Eli Lilly Again Boosts FY24 Outlook - Update

Eli Lilly Again Boosts FY24 Outlook - Update

While reporting financial results for the second quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound, as well as the company's non-incretin medicines.
RTTNews | 142 days ago
Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly CFO Anat Ashkenazi Resigns

Eli Lilly and Co. (LLY) announced Wednesday that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry.
RTTNews | 206 days ago
Eli Lilly Boosts FY24 Outlook - Update

Eli Lilly Boosts FY24 Outlook - Update

While reporting financial results for the first quarter on Tuesday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound and greater visibility into the company's production expansion for the remainder of the year.
RTTNews | 242 days ago
Eli Lilly Q4 Results Top Estimates

Eli Lilly Q4 Results Top Estimates

Drugmaker Eli Lilly reported Tuesday a profit for the fourth quarter that grew 13 percent from last year, reflecting strong Mounjaro sales and higher realized prices. Both adjusted earnings per share and revenues topped analysts' expectations. The company also provided strong revenue guidance for the full-year 2024.
RTTNews | 326 days ago
Tools
Economic Calendar
Market Hours
Interest Rates
Holidays Calendar
Forex Market
Forex Volatility
Forex Correlation
Forex News
forex analysis
COT Data
Liquidity
Forex Calculators
Forex Heat Map
Indicators Heatmap
Community
Community
Systems
Most Popular Systems
Strategies
Contests
Forex Charts
Forex Sentiment
Sentiment Indicator
Reviews
Brokers
Prop Trading Firms
VPS Services
Signal Providers
EA Programming Services
Affiliate Programs
PAMM Broker Services
Rebate Program Services
Trading Platforms
Expert Advisors
Crypto Exchanges
Trading Courses
Brokers
Forex Spreads
Forex Broker Quotes
Forex Broker Swaps
Forex Broker Volume
Forex Broker Promotions Broker News
Platform
Widgets
Features
API
RSS
Stock Portfolio
Affiliate Software
Advanced Charts
Support
FAQ
Help
Contact Us
Report a Bug!
About
Blog
© 2024 Myfxbook Ltd. All Rights Reserved.
HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.